AIM
HBIO icon

Alambic Investment Management’s Harvard Bioscience HBIO Stock Holding History

Alambic Investment Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,540
Closed -$76K – 24
2020
Q3 		$76K Sell
2,540
-1,366
-35% -$45.9K 0.83% 44
2020
Q2 		$121K Buy
3,906
+70
+2% +$1.89K 0.3% 123
2020
Q1 		$85K Sell
3,836
-281
-7% -$7.61K 0.21% 141
2019
Q4 		$126K Sell
4,117
-240
-6% -$6.91K 0.11% 233
2019
Q3 		$134K Sell
4,357
-16,186
-79% -$402K 0.1% 245
2019
Q2 		$411K Sell
20,543
-783
-4% -$22.9K 0.25% 161
2019
Q1 		$919K Buy
21,326
+7,766
+57% +$282K 0.38% 97
2018
Q4 		$431K Buy
13,560
+10,931
+416% +$431K 0.18% 178
2018
Q3 		$138K Buy
+2,629
New +$148K 0.11% 235
2018
Q2 		– Sell
-1,080
Closed -$54K – 389
2018
Q1 		$54K Buy
+1,080
New +$48.4K 0.01% 447

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Alambic Investment Management's HBIO Position: Q4 2020 in Review

Alambic Investment Management sold out of Harvard Bioscience (HBIO) in Q4 2020, closing a stake of 2,540 shares — an estimated $76K sold.

Alambic Investment Management first reported a position in HBIO in Q1 2018 and held it in 10 quarters. The position peaked at $919K in Q1 2019. 81 funds tracked by Wall St. Rank hold HBIO as of Q4 2020.

  • Alambic Investment Management reported no remaining Harvard Bioscience position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 2,540 Harvard Bioscience shares in Q4 2020, an estimated $76K.
  • Alambic Investment Management first reported a position in Harvard Bioscience in Q1 2018 and held it in 10 quarters.
  • Alambic Investment Management's Harvard Bioscience position peaked at $919K in Q1 2019.
  • 81 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.